US Bancorp’s Neuropace NPCE Stock Holding History

US Bancorp’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-13	Closed	-$171	–	4291
2026 Q1	$171	Buy	+13	New	+$195	﹤0.01%	4113
2025 Q3	–	Sell	-135	Closed	-$1.5K	–	4191
2025 Q2	$1.5K	Sell	135 -192	-59%	-$2.4K	﹤0.01%	3907
2025 Q1	$4.02K	Buy	+327	New	+$4.09K	﹤0.01%	3719

Other funds holding NPCE

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

US Bancorp's NPCE Position: Q2 2026 in Review

US Bancorp sold out of Neuropace (NPCE) in Q2 2026, closing a stake of 13 shares — an estimated $171 sold.

US Bancorp first reported a position in NPCE in Q1 2025 and held it in 3 quarters. The position peaked at $4.02K in Q1 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

US Bancorp reported no remaining Neuropace position as of Q2 2026 after selling out during the quarter.
US Bancorp sold 13 Neuropace shares in Q2 2026, an estimated $171.
US Bancorp first reported a position in Neuropace in Q1 2025 and held it in 3 quarters.
US Bancorp's Neuropace position peaked at $4.02K in Q1 2025.
113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.